List view / Grid view
The pandemic has been a game-changer for the pharmaceutical industry, sending the seemingly inexorable globalisation trends into reverse, with Big Pharma increasingly seeking more domestic supply chain options. Here, Karen Winterhalter of Onyx Health shares her expert insights on the impact of this emerging trend on the industry.
Sanofi announces first Digital Accelerator to develop products and solutions that foster the use of digital, data and artificial intelligence.
The approved COVID-19 vaccines and treatments on the list will be monitored to prevent and mitigate the impact of shortages.
Pharma industry calls for support as restrictive pricing measures and rising costs of goods/inflation could undermine the availability of medicines.
The EU’s identification of medicinal products (IDMP) standards implementation was all set to go ahead, when the EMA suddenly announced a change of plan. The DADI user interface will now enable structured data submissions for the EMA PMS, at least for the near future. Drawing on recent dialogue with the…
Ambitions to reach greater numbers of patients with unmet need have fuelled some benevolent plans from bio/pharmaceutical companies ViiV Healthcare and Sandoz.
Recent ABPI figures show Northern Ireland’s life sciences sector supports 19,500 jobs directly, 15,000 jobs indirectly and is worth £2.4 billion.
Setting a new philanthropic benchmark, Pfizer is launching Accord for a Healthier World - an initiative aimed at closing the gap on inequalities with low-income countries.
The agreement between Bavarian Nordic and an undisclosed country aims to ensure sufficient supply of smallpox vaccine to meet the country’s requirements for vaccinating individuals at risk for monkeypox.
A unique partnership, the Access to Oncology Medicines (ATOM) Coalition, has been established to ensure sustainable access to cancer medicines in low- and lower middle-income countries (LLMICs) in the long-term.
![PCI Pharma Services logo on sign outside Canadian facility [Credit: JHVEPhoto/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/PCI-Pharma-Services-300x278.jpg)
![PCI Pharma Services logo on sign outside Canadian facility [Credit: JHVEPhoto/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/PCI-Pharma-Services-e1653043421551.jpg)
Capabilities include the latest in sterile lyophilisation and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends.
![German Chancellor Olaf Scholz at the topping-out ceremony for Bayer's new pharmaceutical production facility in Leverkusen [Credit: Bayer AG].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Olaf-Scholz-300x278.jpg)
![German Chancellor Olaf Scholz at the topping-out ceremony for Bayer's new pharmaceutical production facility in Leverkusen [Credit: Bayer AG].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Olaf-Scholz.jpg)
The new €275 million facility will be used to manufacture medicinal products for cancer and cardiovascular diseases and is scheduled to be ready for operation in 2024.
It seems that sprinkles, commonly known as hundreds and thousands, have undersold their capabilities, as a US scientist identifies their application could uniquely identify billions of individual tablets, potentially thwarting industry fraud.
Winners of ISPE's Facility of the Year Awards (FOYA) 2022 include Janssen, Takeda, CRISPR Therapeutics, Catalent and Iovance Biotherapeutics.
Here, EPR’s Hannah Balfour discusses the latest reports on pharmaceutical counterfeiting and falsification, exploring global and European crime rates, as well as recent counterfeiting incidents reported by Big Pharma.
